PYPD PolyPid
- 4.3600
- +0.2100+5.06%
PolyPid News
Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), PolyPid (PYPD) and GoodRx Holdings (GDRX)
PolyPid Enhances Share Option Plan to Motivate Staff
PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript
Earnings Call Summary | PolyPid(PYPD.US) Q1 2024 Earnings Conference
The following is a summary of the PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript:Financial Performance:PolyPid reported Q1 2024 cash and short-term deposits of $14.5 million.Research and developm
PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript
PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $14 Price Target
PolyPid Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 178.33% HC Wainwright & Co. → $14 Reiterates Buy → Buy 05/01/2024 178.33% HC Wainwright & Co. →
PolyPid Reports Q1 Results
Express News | Corrected-PolyPid Q1 Net Income USD -6.448 Million (Corrects Amount)
Express News | Corrected-PolyPid Q1 Operating Income USD -6.301 Million (Corrects Amount)
Express News | Corrected-PolyPid Q1 Pretax Profit USD -6.441 Million (Corrects Amount)
Express News | Corrected-PolyPid Q1 EPS USD -1.37 (Corrects Amount)
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)
PolyPid Advances Phase 3 Trial, Strengthens Finances
Express News | PolyPid Ltd: Expects That Its Pro Forma Cash Balance Will Be Sufficient to Fund Operations Into Q4 of 2024
PolyPid 1Q Loss $6.45M >PYPD
PolyPid 1Q Loss $6.45M >PYPD
PolyPid 1Q Loss/Shr $1.37 >PYPD
PolyPid 1Q Loss/Shr $1.37 >PYPD
PolyPid | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | PolyPid Q1 2024 GAAP EPS $(1.37) Beats $(1.58) Estimate
Analysis
Price Target
No Data
